← Back to Search

Liver Education About Pain (LEAP) for Liver Cirrhosis

N/A

Waitlist Available

Led By Shari S Rogal, MD, MPH

Research Sponsored by University of Pittsburgh

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 6-12 months start-to-finish

Awards & highlights

No Placebo-Only Group

Summary

This trial tests the LEAP program, a course designed to help patients with liver cirrhosis and chronic pain manage their pain without opioids. The program includes individual and group sessions to teach new pain management skills, set personal goals, and provide social support.

Eligible Conditions

Liver Cirrhosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 6-12 months start-to-finish

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 6-12 months start-to-finish

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 6-12 months start-to-finish for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of participants attending ≥80% of intervention sessions

Overall Satisfaction

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: LEAP Intervention ArmExperimental Treatment2 Interventions

Enrolled patients will participate in 12 weekly sessions led by a health coach to learn self-pain management tools and skills. In addition to 6 individual sessions and 6 optional group sessions, participants will complete activities from the LEAP workbook (provided after enrollment), as tracking is a key component of most pain-self management interventions and is intended to address self-regulation. All patients can continue to use other pain management strategies ("usual care") in order to mimic real-life conditions.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Liver Education About Pain (LEAP)

2022

N/A

~30

Usual Care

1990

Completed Phase 4

~7700